Skip to main content

Advertisement

Table 1 Patients characteristics

From: IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics

Characteristics THA TKA p
  n = 214 n = 160  
Age 65.6 ± 11.7 (25-90) 73.9 ± 8.9 (30-89) <0.00001
   Age75 yr 49   89   <0.00001
   Age < 75 yr 165   71   
Gender(male/female) 34/180   31/129   0.379
BMI(Kg/m2) 24.1 ± 3.8 (15.1-37.7) 25.9 ± 4.3 (13.7-41.4) <0.00001
   BMI30 17   30   0.002
   BMI < 30 197   130   
Risk factors 102/214 (47.7%) 112/160 (70.0%) <0.00001
OA/RA 192/22   129/31   0.013
Seroconvertion of IgG-class Anti-PF4/heparinAb 30/214 (14.0%) 44/160 (27.5%) 0.001
Treatment      
   UFH 60/214 (28.0%) 44/160 (27.5%) 0.909
   LMWH 64/214 (29.9%) 31/160 (19.4%) 0.021
   Fondaparinux 49/214 (22.9%) 32/160 (20.0%) 0.501
   Others 21/214 (9.8%) 29/160 (18.1%) 0.019
Aspirin 16/214 (7.5%) 27/160 (16.9%)  
Warfarin 4/214 (1.9%) 1/160 (0.6%)  
Cilostazol 14/214 (6.5%) 23/160 (14.4%)  
   No medication 20/214 (9.3%) 24/160 (15.0%) 0.093
  1. Abbreviations: BMI; body mass index, TKA; total knee arthroplasty, THA; total hip arthroplasty, OA; osteoarthritis, RA; rheumatoid arthritis, UFH; unfractionated heparin, LMWH; low-molecular weight heparin